Serum lactate dehydrogenase in childhood neuroblastoma: A Pediatric Oncology Group recursive partitioning study

J. J. Shuster, N. B. McWilliams, R. Castleberry, R. Nitschke, E. I. Smith, G. Altshuler, L. Kun, G. Brodeur, V. Joshi, T. Vietti, F. A. Hayes

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

On the basis of an extensive recursive partitioning analysis of 668 patients with newly diagnosed neuroblastoma registered on Pediatric Oncology Group (POG) studies between October 1981 and May 1987, four major subsets of patients were created. Important prognostic factors included the patient's stage of disease, age, and level of serum lactate dehydrogenase (LDH). After adjusting for these factors, no other clinical prognostic factors were significant. The implications for protocol design are that (a) fine tuning of current therapy should be sought for the two favorable disease patient subsets, while (b) novel aggressive therapies are needed for the two unfavorable disease patient subsets where the overwhelming majority are dying. This article may serve as a model for others investigating prognostic factors. The data were divided into two subsets: one was used for an exploratory analysis; the other was used to confirm the exploratory findings. Despite the large number of statistical tests performed, the likelihood that the findings can be attributed to chance can be dismissed as virtually zero.

Original languageEnglish (US)
Pages (from-to)295-303
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number4
DOIs
StatePublished - Jan 1 1992

Fingerprint

Neuroblastoma
L-Lactate Dehydrogenase
Pediatrics
Serum
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum lactate dehydrogenase in childhood neuroblastoma : A Pediatric Oncology Group recursive partitioning study. / Shuster, J. J.; McWilliams, N. B.; Castleberry, R.; Nitschke, R.; Smith, E. I.; Altshuler, G.; Kun, L.; Brodeur, G.; Joshi, V.; Vietti, T.; Hayes, F. A.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 4, 01.01.1992, p. 295-303.

Research output: Contribution to journalArticle

Shuster, JJ, McWilliams, NB, Castleberry, R, Nitschke, R, Smith, EI, Altshuler, G, Kun, L, Brodeur, G, Joshi, V, Vietti, T & Hayes, FA 1992, 'Serum lactate dehydrogenase in childhood neuroblastoma: A Pediatric Oncology Group recursive partitioning study', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 15, no. 4, pp. 295-303. https://doi.org/10.1097/00000421-199208000-00004
Shuster, J. J. ; McWilliams, N. B. ; Castleberry, R. ; Nitschke, R. ; Smith, E. I. ; Altshuler, G. ; Kun, L. ; Brodeur, G. ; Joshi, V. ; Vietti, T. ; Hayes, F. A. / Serum lactate dehydrogenase in childhood neuroblastoma : A Pediatric Oncology Group recursive partitioning study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1992 ; Vol. 15, No. 4. pp. 295-303.
@article{8f72fdfbb7eb4f7c8c580796d4961d6d,
title = "Serum lactate dehydrogenase in childhood neuroblastoma: A Pediatric Oncology Group recursive partitioning study",
abstract = "On the basis of an extensive recursive partitioning analysis of 668 patients with newly diagnosed neuroblastoma registered on Pediatric Oncology Group (POG) studies between October 1981 and May 1987, four major subsets of patients were created. Important prognostic factors included the patient's stage of disease, age, and level of serum lactate dehydrogenase (LDH). After adjusting for these factors, no other clinical prognostic factors were significant. The implications for protocol design are that (a) fine tuning of current therapy should be sought for the two favorable disease patient subsets, while (b) novel aggressive therapies are needed for the two unfavorable disease patient subsets where the overwhelming majority are dying. This article may serve as a model for others investigating prognostic factors. The data were divided into two subsets: one was used for an exploratory analysis; the other was used to confirm the exploratory findings. Despite the large number of statistical tests performed, the likelihood that the findings can be attributed to chance can be dismissed as virtually zero.",
author = "Shuster, {J. J.} and McWilliams, {N. B.} and R. Castleberry and R. Nitschke and Smith, {E. I.} and G. Altshuler and L. Kun and G. Brodeur and V. Joshi and T. Vietti and Hayes, {F. A.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1097/00000421-199208000-00004",
language = "English (US)",
volume = "15",
pages = "295--303",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Serum lactate dehydrogenase in childhood neuroblastoma

T2 - A Pediatric Oncology Group recursive partitioning study

AU - Shuster, J. J.

AU - McWilliams, N. B.

AU - Castleberry, R.

AU - Nitschke, R.

AU - Smith, E. I.

AU - Altshuler, G.

AU - Kun, L.

AU - Brodeur, G.

AU - Joshi, V.

AU - Vietti, T.

AU - Hayes, F. A.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - On the basis of an extensive recursive partitioning analysis of 668 patients with newly diagnosed neuroblastoma registered on Pediatric Oncology Group (POG) studies between October 1981 and May 1987, four major subsets of patients were created. Important prognostic factors included the patient's stage of disease, age, and level of serum lactate dehydrogenase (LDH). After adjusting for these factors, no other clinical prognostic factors were significant. The implications for protocol design are that (a) fine tuning of current therapy should be sought for the two favorable disease patient subsets, while (b) novel aggressive therapies are needed for the two unfavorable disease patient subsets where the overwhelming majority are dying. This article may serve as a model for others investigating prognostic factors. The data were divided into two subsets: one was used for an exploratory analysis; the other was used to confirm the exploratory findings. Despite the large number of statistical tests performed, the likelihood that the findings can be attributed to chance can be dismissed as virtually zero.

AB - On the basis of an extensive recursive partitioning analysis of 668 patients with newly diagnosed neuroblastoma registered on Pediatric Oncology Group (POG) studies between October 1981 and May 1987, four major subsets of patients were created. Important prognostic factors included the patient's stage of disease, age, and level of serum lactate dehydrogenase (LDH). After adjusting for these factors, no other clinical prognostic factors were significant. The implications for protocol design are that (a) fine tuning of current therapy should be sought for the two favorable disease patient subsets, while (b) novel aggressive therapies are needed for the two unfavorable disease patient subsets where the overwhelming majority are dying. This article may serve as a model for others investigating prognostic factors. The data were divided into two subsets: one was used for an exploratory analysis; the other was used to confirm the exploratory findings. Despite the large number of statistical tests performed, the likelihood that the findings can be attributed to chance can be dismissed as virtually zero.

UR - http://www.scopus.com/inward/record.url?scp=0026651430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026651430&partnerID=8YFLogxK

U2 - 10.1097/00000421-199208000-00004

DO - 10.1097/00000421-199208000-00004

M3 - Article

C2 - 1514525

AN - SCOPUS:0026651430

VL - 15

SP - 295

EP - 303

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -